scholarly journals Prognostic Value of C-Reactive Protein-to-Albumin Ratio in Head and Neck Cancer: A Meta-Analysis

Diagnostics ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 403
Author(s):  
Chih-Wei Luan ◽  
Hsin-Yi Yang ◽  
Yao-Te Tsai ◽  
Meng-Chiao Hsieh ◽  
Hsin-Hsu Chou ◽  
...  
Keyword(s):  
Head And Neck ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Head And Neck Cancers ◽  
C Reactive Protein ◽  
Free Survival ◽  
Albumin Ratio ◽  
Reactive Protein ◽  
Distant Metastasis Free Survival ◽  
Disease Free

The C-reactive protein-to-albumin ratio is a proven prognostic predictor of nasopharyngeal carcinoma. However, the role of the C-reactive protein-to-albumin ratio in other head and neck cancers remains unclear. This meta-analysis explored the prognostic value of the C-reactive protein-to-albumin ratio in head and neck cancers. A systematic search was conducted. Outcomes of interest included overall survival, disease-free survival, and distant metastasis–free survival. The hazard ratio with 95% confidence interval was pooled using a random-effects model. A total of 11 publications from the literature were included, allowing for the analysis of 7080 participants. Data pooling demonstrated that pretreatment C-reactive protein-to-albumin ratio had a hazard ratio of 1.88 (95% CI: 1.49−2.37, p < 0.001) for predicting overall survival, 1.91 (95% CI: 1.18−3.08, p = 0.002) for disease-free survival, and 1.46 (95% CI: 1.08−1.96, p = 0.001) for distant metastasis–free survival. Subgroup analysis showed that the C-reactive protein-to-albumin ratio is a significant prognostic marker for various head and neck cancers. An elevated pretreatment C-reactive protein-to-albumin ratio predicts a worse prognosis for patients with head and neck cancers. Therefore, the C-reactive protein-to-albumin ratio could serve as a potential prognostic biomarker facilitating treatment stratification.

scholarly journals Prognostic and Clinicopathological Significance of C-Reactive Protein to Albumin Ratio in Patients With Pancreatic Cancer: A Meta-Analysis

Dose-Response ◽  
2020 ◽  
Vol 18 (2) ◽  
pp. 155932582093129
Author(s):  
Qinfen Xie ◽  
Lidong Wang ◽  
Shusen Zheng
Keyword(s):  
Pancreatic Cancer ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
Cochrane Library ◽  
Survival Outcomes ◽  
C Reactive Protein ◽  
Free Survival ◽  
Albumin Ratio ◽  
Reactive Protein

Background: This meta-analysis explored the correlation between the C-reactive protein to albumin ratio (CAR) and survival outcomes and clinicopathological characteristics in patients with pancreatic cancer. Methods: PubMed, Embase, Web of Science, and Cochrane Library databases were comprehensively searched through October 17, 2019. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used to evaluate the association between CAR and overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS) in pancreatic cancer. Results: The meta-analysis included 11 studies comprising 2271 patients. The pooled results showed that a high CAR was predictive of worse OS (HR = 1.84, 95% CI = 1.65-2.06, P < .001), PFS (HR = 1.53, 95% CI = 1.27-1.85, P < .001), and DFS (HR = 1.77, 95% CI = 1.30-2.41, P < .001). An elevated CAR was also associated with male sex (OR = 1.38, 95% CI = 1.10-1.74, P = .006). Conclusion: Elevated pretreatment CAR effectively predicts inferior survival outcomes in patients with pancreatic cancer and may be a powerful prognostic indicator for these patients.

Prognostic Role of C-Reactive Protein in Breast Cancer: A Systematic Review and Meta-Analysis

2011 ◽  
Vol 26 (4) ◽  
pp. 209-215 ◽  
Author(s):  
Yijie Han ◽  
Feng Mao ◽  
Ying Wu ◽  
Xiaonan Fu ◽  
Wei Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
C Reactive Protein ◽  
Cancer Specific Survival ◽  
Free Survival ◽  
Reactive Protein ◽  
Hazard Ratios ◽  
Disease Free

Background Recent studies have shown that C-reactive protein (CRP) may be associated with breast cancer. The purpose of this study is to summarize the predictive role of CRP for survival in breast cancer as shown in all available studies worldwide. Methods Related studies were identified and evaluated for quality through multiple search strategies. Data were collected from studies comparing overall, cancer-specific, and disease-free survival (OS, CSS, and DFS) in patients with elevated CRP levels and those having lower levels. Studies were pooled, and combined hazard ratios (HRs) of CRP for survival were calculated. Results A total of 10 studies (n=4,502) were included for this meta-analysis (9 for OS, 3 for CSS, and 3 for DFS). For overall and disease-free survival, the pooled HRs of CRP were significant at 1.62 (95% confidence interval [95% CI], 1.20-2.18) and 1.81 (95% CI, 1.44-2.26), respectively. For cancer-specific survival, the pooled HR in higher CRP expression in breast cancer was 2.08 (95% CI, 1.48-2.94), which could strongly predict poorer survival in breast cancer. Conclusions CRP has a critical prognostic value in patients with breast cancer as an inflammation biomarker.

Lymphocyte-to-C-reactive protein ratio is a potential new prognostic biomarker for patients with lung cancer

2020 ◽  
Vol 14 (9) ◽  
pp. 717-726 ◽  
Author(s):  
Yuan He ◽  
Rui Gong ◽  
Kun-Wei Peng ◽  
Li-Zhen Liu ◽  
Li-Yue Sun ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
Inflammatory Factors ◽  
C Reactive Protein ◽  
First Line ◽  
Protein Ratio ◽  
Free Survival ◽  
Reactive Protein ◽  
Disease Free

Aim: To compare and evaluate the prognostic value of various pretreatment combinations of inflammatory factors in patients with lung cancer (LC). Materials & methods: This study enrolled 1005 patients with LC and categorized into a discovery cohort and a validation cohort. Results: A combination of Lymphocyte-to-C-reactive protein levels (LCR) demonstrated the highest correlation with poor first-line progression-free survival (PFS) and overall survival (OS) (p < 0.05), but not disease-free survival (p > 0.05) compared with other parameters in LC patients. Decreased preoperative LCR was an independent prognostic factor for first-line PFS and OS (p < 0.05), but not disease-free survival (p > 0.05) in patients. Conclusion: Pretreatment LCR is a promising biomarker for first-line PFS and OS in patients with LC.

scholarly journals C-Reactive Protein to Albumin Ratio in Colorectal Cancer: A Meta-Analysis of Prognostic Value

Dose-Response ◽  
2019 ◽  
Vol 17 (4) ◽  
pp. 155932581988981 ◽  
Author(s):  
Qiang-ping Zhou ◽  
Xiu-jiang Li
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Tumor Diameter ◽  
C Reactive Protein ◽  
Free Survival ◽  
Albumin Ratio ◽  
Reactive Protein ◽  
Serum Carcinoembryonic Antigen

Background: The relationship between pretreatment C-reactive protein to albumin ratio (CAR) and colorectal cancer (CRC) prognosis has been extensively studied in various tumors. However, little is known on CAR and its association with prognosis in CRC. This study aims to investigate the prognostic value of pretreatment CAR in CRC. Methods: We conducted a systematic search of MEDLINE, EMBASE, and Cochrane Library databases for eligible studies evaluating the associations of CAR with survival and/or clinicopathology of CRC. Overall survival (OS), disease-free survival (DFS), relapse-free survival (RFS), and clinicopathological features were synthesized and compared. Results: Nine studies including 3431 patients were analyzed in this meta-analysis. Pooled results showed that elevated pretreatment CAR was associated with poor OS (pooled hazards ratio [HR]: 2.18, 95% confidence interval [CI]: 1.70-2.78, P < .001) and DFS/RFS (pooled HR: 2.36, 95% CI: 1.40-3.98, P < .001). Moreover, elevated pretreatment CARs were correlated with male patients, large tumor diameter, late III-IV tumor node metastasis stage tumors, high serum carcinoembryonic antigen and carbohydrate antigen 19-9, and presence of lymphatic invasion and venous invasion. Conclusion: Elevated pretreatment CAR could be an adverse prognostic indicator in patients with CRC.

scholarly journals LARYNGECTOMY: FROM STRIDOR TO SURVIVAL- OUR EXPERIENCE

2011 ◽  
Vol 01 (01/03) ◽  
pp. 75-80
Author(s):  
Satheesh Kumar Bhandary ◽  
Vadish S. Bhat ◽  
M. Shwetha Shenoy
Keyword(s):  
Head And Neck ◽  
Laryngeal Cancer ◽  
Total Laryngectomy ◽  
Disease Free Survival ◽  
The Body ◽  
Head And Neck Cancers ◽  
Free Survival ◽  
Speech Rehabilitation ◽  
The World ◽  
Disease Free

AbstractLaryngeal cancer is among the commonest cancers in the body. It constitutes one fifth of all head and neck cancers. India accounts for 17% of the world burden. Even though it is curable in early stages, majority of them in India present in the later stages due to ignorance and poverty. The mainstay of treatment in advanced cases is total laryngectomy, with or without post operative radiotherapy which results in loss of voice. However, by speech rehabilitation and by modification of the technique in the form of near total laryngectomy, these patients can be assured of good quality disease free survival.

scholarly journals C-Reactive Protein As a Marker of Melanoma Progression

2015 ◽  
Vol 33 (12) ◽  
pp. 1389-1396 ◽  
Author(s):  
Shenying Fang ◽  
Yuling Wang ◽  
Dawen Sui ◽  
Huey Liu ◽  
Merrick I. Ross ◽  
...  
Keyword(s):  
Disease Free Survival ◽  
Hazard Ratio ◽  
Stage I ◽  
C Reactive Protein ◽  
Free Survival ◽  
Reactive Protein ◽  
Unit Increase ◽  
The Relationship ◽  
Disease Free ◽  
Combined Data

Purpose To investigate the association between blood levels of C-reactive protein (CRP) in patients with melanoma and overall survival (OS), melanoma-specific survival (MSS), and disease-free survival. Patients and Methods Two independent sets of plasma samples from a total of 1,144 patients with melanoma (587 initial and 557 confirmatory) were available for CRP determination. Kaplan-Meier method and Cox regression were used to evaluate the relationship between CRP and clinical outcome. Among 115 patients who underwent sequential blood draws, we evaluated the relationship between change in disease status and change in CRP using nonparametric tests. Results Elevated CRP level was associated with poorer OS and MSS in the initial, confirmatory, and combined data sets (combined data set: OS hazard ratio, 1.44 per unit increase of logarithmic CRP; 95% CI, 1.30 to 1.59; P < .001; MSS hazard ratio, 1.51 per unit increase of logarithmic CRP; 95% CI, 1.36 to 1.68; P < .001). These findings persisted after multivariable adjustment. As compared with CRP < 10 mg/L, CRP ≥ 10 mg/L conferred poorer OS in patients with any-stage, stage I/II, or stage III/IV disease and poorer disease-free survival in those with stage I/II disease. In patients who underwent sequential evaluation of CRP, an association was identified between an increase in CRP and melanoma disease progression. Conclusion CRP is an independent prognostic marker in patients with melanoma. CRP measurement should be considered for incorporation into prospective studies of outcome in patients with melanoma and clinical trials of systemic therapies for those with melanoma.

scholarly journals The prognostic value of C-reactive protein/albumin ratio in nasopharyngeal carcinoma: a meta-analysis

2018 ◽  
Vol 38 (6) ◽  
Author(s):  
Nan Gao ◽  
Ruo-Nan Yang ◽  
Zhen Meng ◽  
Wan-Hai Wang
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Cochrane Library ◽  
C Reactive Protein ◽  
Poor Overall Survival ◽  
Free Survival ◽  
Albumin Ratio ◽  
Reactive Protein ◽  
Hazard Ratios

The C-reactive protein/albumin ratio (CRP/Alb ratio) has been reported to have promising prognostic value in several cancers. The current meta-analysis was conducted to better define the prognostic value of CRP/Alb ratio in patients with nasopharyngeal carcinoma (NPC). The Web of Science, Embase, Cochrane Library databases, and PubMed were searched up to 25 February 2018 for the information on CRP/Alb ratio and outcomes of NPC. Pooled hazard ratios (HRs) and corresponding 95% confidence intervals (95% CIs) were used to evaluate the association between CRP/Alb ratio and survival outcomes in NPC. A total of five studies with 5533 patients with NPC were included. Pooled results showed that high CRP/Alb ratio was associated with poor overall survival (OS) (HR = 1.51, 95% CI: 1.30–1.75, P<0.001) and poor distant metastasis-free survival (DMFS) (HR = 1.23, 95% CI: 1.07–1.43, P=0.005). Subgroup analyses showed that patients with higher CRP/Alb ratio have worse OS in NPC. In conclusion, elevated CRP/Alb ratio was associated with worse prognosis in patients with NPC.

scholarly journals The Value of C-Reactive Protein, C-Reactive Protein Kinetics and C-reactive Protein to Albumin Ratio on Prognosis in Newly Diagnosed Indolent B-cell Non-Hodgkin Lymphoma

2020 ◽  
Author(s):  
Huimin Zhang ◽  
Xiangxiang Zhou ◽  
Xiang Sun ◽  
Yang Han ◽  
Xinting Hu ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Post Treatment ◽  
C Reactive Protein ◽  
Free Survival ◽  
Albumin Ratio ◽  
Reactive Protein ◽  
Non Hodgkin Lymphoma

Abstract Objective: This study aimed to determine prognostic significance of C-reactive protein (CRP), CRP kinetics and CRP to albumin ratio (CAR) in indolent B-cell non-Hodgkin lymphoma (B-iNHL) patients. Methods: The association among these blood makers and overall survival (OS), disease-free survival (DFS), progression-free survival (PFS) were analyzed in 243 B-iNHL patients. OS, DFS and PFS were determined by Kaplan–Meier curves. Cox proportional analysis was performed to examine the prognostic significance of clinicopathological variables. Results: Multivariate analyses identified that elevated pretreatment CRP (HR: 5.110, 95% CI: 1.904-13.717, p=0.001), post-treatment CRP (HR: 5.826, 95% CI: 1.659-20.458, p=0.006), continuously elevated CRP (HR: 6.461, 95% CI: 2.620-15.930, p<0.001) and elevated CAR (HR: 3.768, 95% CI: 1.415-10.034, p=0.008) had association with worse OS. Likewise, elevated pretreatment CRP (HR: 3.767, 95% CI: 1.777-7.984, p=0.001), post-treatment CRP (HR: 2.384, 95% CI: 1.027-5.534, p=0.043), ever-elevated CRP (HR: 2.425, 95% CI: 1.105-5.322, p=0.027), continuously elevated CRP (HR: 4.748, 95% CI: 2.114-10.660, p<0.001) and elevated CAR (HR: 2.824, 95% CI: 1.336-5.971, p=0.007) were in independent significance with worse DFS. Elevated pretreatment CRP (HR: 2.606, 95% CI: 1.338-5.076, p=0.005), ever-elevated CRP (HR: 2.086, 95% CI: 1.040-4.188, p=0.039), continuously elevated CRP (HR: 3.296, 95% CI: 1.594-6.818, p=0.001) and elevated CAR (HR: 1.991, 95% CI: 1.021-3.882, p=0.043) were determined in independent significance with poor PFS. The effect was statistically significant in both follicular lymphoma (FL) and chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/ SLL) patients.Conclusions: In conclusion, we demonstrate that CRP level, CRP kinetics and CAR could be potential prognostic indicators with independent significance in patients with B-iNHL, also in FL and CLL/ SLL subgroups. CRP and CAR make an implementation for prognostic evaluation more easily and effectively in B-iNHL patients.

Sign in / Sign up

Export Citation Format

Share Document